Cardiovascular

TAXUS DES Trials Results: How Long Should Thienopyridine Be Used After Drug Eluting Stent?

Gregg Stone
Gregg Stone
REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GREGG STONE, Columbia University, New York
New light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents. Gregg Stone presented data from the TAXUS DES trials which looked at patients surviving more than a year after receiving either paclitaxel-eluting or bare metal stents. After his talk at the American Heart Association he discussed his findings with Sarah Maxwell.

Download this interview

Similar Interviews

  • Late-Stent Throbosis Risk after Clopidogrel Withdrawal: Greater in Drug Eluting Stents
  • Matthias Pfisterer, University Hospital Basel American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta. Abstract Number: 422-11. Lancet 2005:366:921 Clopidogrel

  • Audio Journal of Cardiovascular Medicine: Sirolimus-Eluting Better Than Uncoated Stents for Primary Angioplasty">Audio Journal of Cardiovascular Medicine: Sirolimus-Eluting Better Than Uncoated Stents for Primary Angioplasty
  • CHRISTIAN SPAULDING, Cochin Hospital, Paris REFERENCE: N Engl J Med 2006;355:1093, 1105,1169 Two leading articles in the same edition of the New

  • Primary Angioplasty: Sirolimus Eluting Stent Cuts MACE Rates In Half
  • Christian Spaulding, Rene Descartes University American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta Primary PCI is even more effective

    Post a comment